Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00383812
Status:
UNKNOWN
Last Update Posted:
2006-10-04
First Post:
2006-10-03
Brief Title:
Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
Sponsor:
Asan Medical Center
Organization:
Asan Medical Center
Study Overview
Official Title:
Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
Status:
UNKNOWN
Status Verified Date:
2006-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1 Primary objectives
a To evaluate the Effects of intravitreal Bevacizumab on polypoidal choroidal vasculopathyPCV
2 Secondary objectives
1 To assess the changes in visual acuity
2 To assess the change in lesion characteristics of PCV
size of PCV
fluorescein leakage
foveal thickness
3 To investigate the safety of intravitreal Bevacizumab in patients with PCV
4 To assess the effect of intravitreal Bevacizumab on the recurrence rate and the the incidence of submacular hemorrhage in patients with PCV
a To evaluate the Effects of intravitreal Bevacizumab on polypoidal choroidal vasculopathyPCV
2 Secondary objectives
1 To assess the changes in visual acuity
2 To assess the change in lesion characteristics of PCV
size of PCV
fluorescein leakage
foveal thickness
3 To investigate the safety of intravitreal Bevacizumab in patients with PCV
4 To assess the effect of intravitreal Bevacizumab on the recurrence rate and the the incidence of submacular hemorrhage in patients with PCV
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None